Industry
Biotechnology
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Loading...
Open
8.23
Mkt cap
156M
Volume
303K
High
8.85
P/E Ratio
-6.47
52-wk high
12.10
Low
8.02
Div yield
N/A
52-wk low
5.85
Portfolio Pulse from Benzinga Insights
March 14, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
March 05, 2024 | 1:21 pm
Portfolio Pulse from Benzinga Newsdesk
November 08, 2023 | 1:10 pm
Portfolio Pulse from Benzinga Insights
November 08, 2023 | 1:10 pm
Portfolio Pulse from Benzinga Insights
October 17, 2023 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 21, 2023 | 12:01 pm
Portfolio Pulse from Benzinga Newsdesk
September 15, 2023 | 10:10 am
Portfolio Pulse from Benzinga Newsdesk
September 12, 2023 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
August 17, 2023 | 12:02 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.